TherapeuticsMD, Inc.
TXMD
$2.21
-$0.03-1.34%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -8.72% | 84.22% | 33.88% | 43.33% | 306.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.72% | 84.22% | 33.88% | 43.33% | 306.84% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -8.72% | 84.22% | 33.88% | 43.33% | 306.84% |
| SG&A Expenses | -10.30% | -22.66% | 100.80% | -24.89% | -4.70% |
| Depreciation & Amortization | -1.04% | -1.05% | -3.00% | 0.00% | -46.67% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.60% | -20.92% | 90.19% | -23.19% | -10.05% |
| Operating Income | 12.23% | 73.69% | -210.58% | 65.54% | 72.94% |
| Income Before Tax | -69.91% | 115.42% | -798.80% | 108.82% | 151.90% |
| Income Tax Expenses | -- | -- | 203.23% | -- | -- |
| Earnings from Continuing Operations | -69.91% | 116.19% | -636.84% | 108.82% | 151.90% |
| Earnings from Discontinued Operations | -250.00% | 52.94% | -105.07% | 342.86% | 115.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -71.87% | 114.55% | -345.63% | 124.96% | 150.55% |
| EBIT | 12.23% | 73.69% | -210.58% | 65.54% | 72.94% |
| EBITDA | 17.04% | 83.72% | -311.32% | 73.79% | 77.68% |
| EPS Basic | -71.85% | 114.51% | -344.29% | 124.81% | 150.37% |
| Normalized Basic EPS | -67.35% | 117.83% | -677.55% | 114.33% | 157.89% |
| EPS Diluted | -80.67% | 113.33% | -360.27% | 118.66% | 150.37% |
| Normalized Diluted EPS | -67.69% | 117.52% | -677.55% | 114.33% | 157.89% |
| Average Basic Shares Outstanding | 0.00% | 0.19% | 0.37% | 0.36% | 0.36% |
| Average Diluted Shares Outstanding | 0.60% | 0.76% | 0.37% | 0.36% | 0.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |